AXLA

AXLA US Stock
$4.2
Open: $4.16 High: $4.32 Low: $4.01 Close: $4.2
Range: 2021-06-23 - 2021-06-24
Volume: 485,852
Market: Open
Powered by Finage Stock APIDelayed data
AXLA
  • CEO:
  • Employees:
  • Sector:
  • Industry:
AXLA News
Latest news about the AXLA
  • Axcella Accumulating Assets; Multiple Therapies in the Pipeline

    Time in the market beats timing the market, as the old adage goes. This platitude plays particularly well regarding biotechnology stocks, as one will want to be invested in these stocks well before any big news comes out. Axcella Health Inc. (AXLA) is no exception, as the company is making strides on breakthrough therapies. Analysts are bullish on the stock. One such analyst is Keay Nakae of Chardan Capital Markets, who assigned a Buy rating and a price target of $10. While this price target rep

    View More →
  • 2 “Strong Buy” Penny Stocks That Could Rally to $10 (or More)

    Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi

    View More →
  • Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture

    Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, today announced the closing of a Series C financing round totaling $88.9 million. Joining founder and principal backer Flagship Pioneering is Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others. With this financing, Invaio has raised more than $142 million since its founding in 2018.

    View More →
  • Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that positive data from the company’s AXA1665-002 clinical study were presented last night at the Digestive Disease Week (DDW) 2021 Annual Meeting by Dr. Arun Sanyal, Professor in the Virginia Commonwealth University (VCU) Department of Internal Medicine and Education Core Director in the VCU Center for Clinical and Translational Research.

    View More →
  • Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening

    Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced today an agreement with the world-renowned Fundecitrus, Fund for Citrus Protection, located in Araraquara, Brazil. The agreement focuses on the collaboration to evaluate the use of a novel natural peptide to control the devastating disease Citrus Greening (HLB) in Brazilian citrus trees.

    View More →
  • Should You Take Comfort From Insider Transactions At Axcella Health Inc. (NASDAQ:AXLA)?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

    View More →
  • Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targeted oral product candidate for the treatment of NASH.

    View More →
  • Axcella Reports First Quarter Financial Results and Provides Business Update

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.

    View More →
  • Axcella Health, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Axcella Health, Inc. (NASDAQ:AXLA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 8:30 AM Eastern Time.

    View More →
  • Axcella to Report First Quarter 2021 Financial Results on May 6, 2021

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

    View More →
  • Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company’s product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE):

    View More →
  • FDA Approves New Drug Application For Axcella’s AXA1125; Shares Pop 10%

    Shares of Axcella Health jumped 10.2% on April 13 after the clinical-stage biotechnology company announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AXA1125, the multi-targeted oral product candidate designed for the treatment of non-alcoholic steatohepatitis (NASH). Axcella (AXLA) CEO Bill Hinshaw said, “This IND follows close on the heels of AXA1665’s IND clearance earlier this year, ushering in an exciting new era for Axcella as we seek to tackle a variety of complex diseases and address important unmet needs for patients utilizing multi-targeted EMM compositions.” Following the FDA clearance, Axcella is likely to enter directly into a Phase 2b clinical trial in the second quarter of 2021. These clinical trials will evaluate the efficacy of AXA1125 in adult patients with biopsy-confirmed F2/F3 NASH. NASH is the most severe form of non-alcoholic fatty liver disease (NAFLD) related to significant morbidity and mortality globally. This disease is expected to impact up to 40 million Americans, including 10% of children. Notably, this chronic and progressive liver disease currently has no approved therapies in the United States. (See Axcella stock analysis on TipRanks) Following the development, Wedbush analyst Liana Moussatos reiterated a Buy rating and a price target of $11 (136% upside potential) on the stock. According to Moussatos, “the positive AXA1125-003 results, coupled with the oral route of administration and favorable tolerability profile to date, reinforce AXA1125’s competitive position among future NASH treatments.” The consensus rating among analysts is a Strong Buy based on 4 unanimous Buys. The average analyst price target stands at $12.75 and implies upside potential of 173.6% to current levels. Shares have gained 35.5% over the past year. Furthermore, TipRanks data shows that financial blogger opinions are 100% Bullish on Axcella, compared to a sector average of 69%. Related News: Hologic To Snap Up Mobidiag For $795M, Provide Growth Platform PAR Technology Buys Punchh For $500M; Shares Pop 25.5% Orbcomm To Be Acquired By GI Partners For $1.1B; Shares Pop 52% More recent articles from Smarter Analyst: Wall Street Roundup: Bullish & Bearish Calls Of The Day Score Media And Gaming's 2Q Revenue Misses Estimates; Shares Plunge 3% good natured Products Announces Preliminary Results For 1Q Galiano Gold Reports Preliminary Results For 1Q

    View More →
  • Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has achieved a key milestone with U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for AXA1125, enabling the company to proceed directly into a Phase 2b clinical trial. AXA1125 is Axcella’s multi-targeted oral product candidate for nonalcoholic steatohepatitis (NASH), a chronic and progressive liver disease impacting up to 40 million people in the U.S. alone.

    View More →
  • Axcella's Multi-Targeted Approach To Treat Complex Diseases Holds Transformational Potential

    Axcella Health (NASDAQ: AXLA) was one of the sponsors for the Benzinga Biotech Global Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Precision medicine — providing the right treatment, for the right patient, at the right time — is saving lives. To battle diseases that are tough to treat, biotech companies typically use a small molecule or a biological drug to target one pathway within the body. Though, traditional single-target mechanisms may only address an individual metabolic or disease node. There is another class of important and promising candidates that are overlooked: multi-target drugs powered by endogenous metabolic modulators (EMMs). Axcella Health, a Massachusetts-based clinical-stage biotechnology company, is pioneering a multi-targeted approach using EMM compositions to treat complex diseases. What Are EMMs? Endogenous metabolic modulators, or EMMs, are a critical set of naturally occurring molecules that have a fundamental role in biology. EMMs include a broad set of molecular families, including Axcella’s current focus: amino acids and their derivatives. Amino acids serve as master regulators and signaling agents for metabolic pathways throughout the body while also having a well-established track record for clinical safety and tolerability. They can help provide the ability for cells and organs to: Select fuel sources. Create biomolecules such as nucleic acids, proteins, lipids and carbohydrates. Sense the availability of nutrients. Eliminate waste products. Produce immune responses. Activate signaling pathways. Unique Approach Leveraging these master regulators and signaling agents, Axcella has compiled a portfolio of multi-targeted product candidates that hold transformational potential, working with the body’s systems to tackle complex diseases such as nonalcoholic steatohepatitis (NASH) and overt hepatic encephalopathy (OHE). Photo: Axcella Health Drug Candidate To Treat NASH AXA1125 is Axcella’s drug candidate to treat NASH. Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease that is caused by the accumulation of liver fat, which can lead to complications such as cirrhosis and liver cancer. Between 3% to 12% of adults in the U.S. (up to 40 million) suffer from NASH. While there are currently no FDA-approved drugs to combat this chronic and deadly disease, virtually all analysts expect NASH to become a multi-billion-dollar market over the next decade. Designed just four years ago, AXA1125 is now set to enter a Phase 2b clinical trial. Axcella believes the trial’s initiation will demonstrate distinct advantages of the company’s differentiated approach. For instance, while it normally would take seven or more years to reach Phase 2 development with a drug candidate, Axcella is accomplishing this in roughly half of the time. The company also is armed with more data entering this phase of development than many companies. Drug Candidate To Target The Reduction In Risk Of Recurrent OHE AXA1665 is Axcella’s product candidate for the prevention of recurring OHE. OHE is a manifestation of cirrhosis in which patients are severely and cognitively impaired to where they are unable to care for themselves and may ultimately become comatose. It is estimated that about one-third of cirrhotic patients experience at least one OHE event during the course of their disease, leading to roughly $1 billion being spent annually on OHE treatments in the U.S. Additionally, many of these patients experience repeated events even while on today’s approved medicines, namely lactulose and rifaximin. Axcella believes this is because these agents focus on only one of the disease drivers, namely elevated ammonia, and because tolerability is a challenge and thus compliance is limited. AXA1665 holds the potential to improve the standard of care by addressing this disease more comprehensively and safely. The drug candidate is currently entering a Phase 2 clinical trial. Financials As of December 31, 2020, cash, cash equivalents and marketable securities totaled $107.3 million, compared to $92.1 million on December 31, 2019. The increase is primarily the result of net proceeds from the company’s follow-on stock offering that was completed in May 2020. Axcella expects that its cash balance will be sufficient to meet the company’s operating needs into the third quarter of 2022. To learn more about Axcella Health, you can visit its website here. Photo by National Cancer Institute on Unsplash See more from BenzingaClick here for options trades from BenzingaHow Status Money Is Rewriting the Fintech Playbook© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer

    Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced today the appointment of Peleg Chevion as President and Chief Commercial Officer. Chevion, who joined the company in late 2020, will focus on accelerating the commercial activities of the company.

    View More →
  • Axcella Health Tanks 4% On Wider-Than-Feared Quarterly Loss

    Axcella Health dipped 3.8% to close at $5.57 on March 17 after the clinical-stage biotechnology company posted a larger-than-expected loss in the fourth quarter. Axcella Health (AXLA) incurred a loss of $0.40 per share in 4Q, compared to the $0.36 loss per share estimated by analysts. The company reported a loss of $0.68 per share in the prior-year quarter. The company’s research and development expenses decreased 1.9% year-over-year to $10.6 million, while general and administrative expenses declined 15.2% to $3.9 million. (See Axcella Health stock analysis on TipRanks) Axcella Health CEO Bill Hinshaw said, “We were pleased to advance our preparations in the fourth quarter with a successful Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding our non-alcoholic steatohepatitis (NASH) candidate, AXA1125, and began 2021 with our first investigational new drug (IND) clearance for AXA1665, our candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE).” Following the 4Q results, B.Riley Financial analyst Mayank Mamtani maintained a Buy rating and a price target of $14 (151.4% upside potential). Mamtani said, “AXA1665 IND clearance marks an important milestone, validating AXLA’s capital efficient, accelerated drug development model to rapidly advance molecules to late-stage programs.” Axcella Health shares have exploded 147.6% over the past year, while the stock still scores a Strong Buy consensus rating based on 4 unanimous Buys. That’s alongside an average analyst price target of $14.75, which implies 164.8% upside potential to current levels. Related News: Lennar’s 1Q Results Top Analysts’ Expectations As Housing Market Picks Up Southwest Airlines Provides Operational And Financial Business Update; Shares Gain Johnson & Johnson’s Single-Dose COVID-19 Vaccine Granted Emergency Use Listing By WHO More recent articles from Smarter Analyst: Signet Jewelers’ Sales Outlook Tops Estimates After 4Q Beat; Shares Jump Pre-Market Gilead, Novo Nordisk Expand NASH Collaboration Black Knight Expands Offerings With Acquisition Of Mortgage Broker LOS Accenture Boosts Sustainability Services With Investment In Arabesque S-Ray

    View More →
  • Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.

    View More →
  • Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and full year 2020 financial results and other business updates on March 17, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

    View More →
  • Axcella Announces Alison D. Schecter, M.D., as President of R&D

    Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakravarthy, M.D., Ph.D., has decided to step down as the company’s Chief Medical Officer to pursue another opportunity.

    View More →
  • Axcella Announces Upcoming Presentations at NASH-TAG 2021

    Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced three upcoming presentations at the NASH-TAG 2021 Conference, which is taking place March 11-13. Among the information to be shared by Axcella at this event will be clinical data regarding AXA1125, the company’s multi-targeted product candidate for nonalcoholic steatohepatitis (NASH) that is entering Phase 2b clinical development. Additionally, new in-depth insights into the mechanism of action for AXA1125 will be provided. The presentation details are as follows:

    View More →